Glaukos completes Avedro acquisition

Glaukos Corporation has completed acquisition of Avedro, Inc., according to a press release.

Under the terms of the all-stock transaction agreement, which was announced in August, Glaukos gained Avedro’s FDA-approved Photrexa keratoconus therapy.

“Today marks an important day for Glaukos as Avedro will serve as the cornerstone of our new corneal health franchise,” Thomas Burns, Glaukos president and CEO, said. “This transaction pairs two highly complementary, hybrid pharma and device organizations, combining Avedro’s novel bioactivated pharmaceutical solutions and R&D capabilities with Glaukos’ global commercial scale, proven market-building and shared reimbursement expertise, and extensive clinical and regulatory infrastructure.”

 

 

Glaukos Corporation has completed acquisition of Avedro, Inc., according to a press release.

Under the terms of the all-stock transaction agreement, which was announced in August, Glaukos gained Avedro’s FDA-approved Photrexa keratoconus therapy.

“Today marks an important day for Glaukos as Avedro will serve as the cornerstone of our new corneal health franchise,” Thomas Burns, Glaukos president and CEO, said. “This transaction pairs two highly complementary, hybrid pharma and device organizations, combining Avedro’s novel bioactivated pharmaceutical solutions and R&D capabilities with Glaukos’ global commercial scale, proven market-building and shared reimbursement expertise, and extensive clinical and regulatory infrastructure.”